The envelope (E) proteins of Zika virus (ZIKV) and dengue virus (DENV) present a high degree of homology, which can lead to cross-reactive antibodies that exacerbate disease through antibody-dependent enhancement. This enormously challenges the development of effective ZIKV vaccines.